NDAORALTABLET, DELAYED RELEASEPriority Review
Approved
Nov 2018
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AEMCOLO (rifamycin sodium) is an oral, delayed-release tablet antibiotic approved in 2018 for treating traveler's diarrhea caused by non-invasive strains of E. coli. Rifamycin is a rifamycin-class antibiotic that acts locally in the gastrointestinal tract to inhibit bacterial RNA polymerase. This product targets patients with acute infectious gastroenteritis in specific geographic or travel contexts.
$0.006BPart D
Post-LOEPost-LOEProduct is in post-LOE phase with minimal Medicare Part D spending; expect maintenance-mode teams focused on lifecycle management rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on AEMCOLO at Cosmo Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.